Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1

摘要: Surgical excision of colorectal cancer at early clinical stages is highly effective, but 20-30% patients relapse. Therefore, it relevance to identify high risk for recurrence, who would benefit from adjuvant chemotherapy. The objective this study was prognostic and/or predictive methylation markers in stage II patients. we selected six gene promoters (FZD9, PCDH10 (protocadherin 10), SFRP2, SPARC (secreted protein acidic and rich cysteine), UCHL1 (ubiquitin carboxyl-terminal hydrolase 1), WIF1) analysis formalin-fixed, paraffin-embedded primary tumor samples (n=143) were enrolled a prospective randomized phase III trial the Austrian Breast Colorectal Study Group. Patients chemotherapy with 5-fluorouracil leucovorin or surveillance only. Survival analyses revealed that combined evaluation three (PCDH10, SPARC, UCHL1) showed differential effects regard disease-free survival overall two treatment groups (significance level 0.007). In arm, statistically insignificant trend without toward longer observed (P=0.069 P=0.139 survival). Contrary, arm their had shorter (P=0.031 P=0.003 survival), indicating effect group (test interaction, P=0.006 P=0.018 These results indicate promoter status PCDH10, may be used both as molecular marker and, therefore, facilitate decisions cancer.